A closer look at CUBN: The Intrinsic Factor-Cobalamin Receptor as a Drug Target and Biomarker

Target Name: CUBN

NCBI ID: G8029

A closer look at CUBN: The Intrinsic Factor-Cobalamin Receptor as a Drug Target and Biomarker

Introduction

Cobalamin (Vitamin B12) is a critical that plays a vital role in the production of red blood cells, nerve function, and DNA synthesis. It is obtainable from food sources such as meat, fish, eggs, and dairy products, but our bodies ' natural stores of cobalamin deplete rapidly, and individuals may experience symptoms of cobalamin deficiency, including fatigue, weakness, numbness and tingling in the hands and feet, difficulty with balance, and anemia.

Recent studies have identified the Intrinsic Factor-Cobalamin Receptor (CFTR) as a potential drug target and biomarker for various neurological and cardiovascular disorders. This protein, located on the surface of brain cells, plays a crucial role in regulating the levels of cobalamin in the body. Imbalances in CFTR function have been implicated in a range of neurodegenerative diseases, including Alzheimer's, Parkinson's, and multiple sclerosis.

Drug Target: The CFTR

The CFTR is a transmembrane protein that consists of an extracellular portion and an intracellular portion. The extracellular portion consists of a N-terminus, a catalytic center, and a C-terminus that contains a zinc ion-dependent transcription factor-interactive domain (TAD ). The intracellular portion includes a transmembrane region and an ion channel responsible for the regulation of cobalamin levels.

CFTR function is regulated by multiple intracellular signaling pathways, including the TGF-β and Wnt signaling pathways. These pathways involve the interplay of various transcription factors, including NF-kappa-B, AP-1, and STAT3. CFTR has been shown to play a critical role in the regulation of cobalamin homeostasis, by interacting with various nuclear factor kappa B (NFKB) and nuclear transcription factor acetyltransferase 2 (Nrf2) subunits.

Biomarker: The CFTR

Studies have demonstrated that individuals with genetic mutations, such as those in the CFTR gene, have altered CFTR function and increased risk of developing neurodegenerative diseases. The most striking example is the increased risk of developing Alzheimer's disease in individuals with a specific genetic mutation, called the ApoE蔚4蔚4 allele. This is thought to result from the decreased function of CFTR, which allows for an increased accumulation of beta-amyloid peptides and neurofibrillary tangles in the brain.

In addition to its role in the development of neurodegenerative diseases, the CFTR has also been shown to be a potential biomarker for various diseases, including cancer. Studies have shown that individuals with certain genetic mutations, such as those in the TP53 gene, have decreased CFTR function and increased risk of developing cancer. This is thought to result from the decreased regulation of cobalamin homeostasis by the CFTR, which allows for an increased risk of DNA damage and cancer development.

Conclusion

The CFTR, as a drug target and biomarker, has the potential to revolutionize our understanding of neurodegenerative diseases. By targeting the regulation of cobalamin homeostasis by the CFTR, researchers may be able to develop new treatments for a range of disorders, including Alzheimer's, Parkinson's , and multiple sclerosis. Additionally, the CFTR's role in the regulation of cobalamin homeostasis may have implications for the development of cancer, and may be a potential biomarker for this disease as well.

In conclusion, the Intrinsic Factor-Cobalamin Receptor (CFTR) is a protein that plays a crucial role in regulating the levels of cobalamin in the body. Its function is regulated by multiple intracellular signaling pathways, including TGF-β and Wnt signaling pathways, and has been implicated in the development of various neurodegenerative diseases. Additionally, the CFTR has also been shown to be a potential biomarker for a range of diseases, including cancer. As such, targeting the CFTR with drugs or other therapeutic approaches may have significant implications for the treatment of neurodegenerative diseases and cancer.

Protein Name: Cubilin

Functions: Endocytic receptor which plays a role in lipoprotein, vitamin and iron metabolism by facilitating their uptake (PubMed:9572993, PubMed:10371504, PubMed:11717447, PubMed:11606717, PubMed:14576052). Acts together with LRP2 to mediate endocytosis of high-density lipoproteins, GC, hemoglobin, ALB, TF and SCGB1A1. Acts together with AMN to mediate endocytosis of the CBLIF-cobalamin complex (PubMed:9572993, PubMed:14576052). Binds to ALB, MB, Kappa and lambda-light chains, TF, hemoglobin, GC, SCGB1A1, APOA1, high density lipoprotein, and the CBLIF-cobalamin complex. Ligand binding requires calcium (PubMed:9572993). Serves as important transporter in several absorptive epithelia, including intestine, renal proximal tubules and embryonic yolk sac. May play an important role in the development of the peri-implantation embryo through internalization of APOA1 and cholesterol. Binds to LGALS3 at the maternal-fetal interface

More Common Targets